Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model Kentaro MiyakeTasuku KiyunaRobert M. Hoffman Original Article 13 February 2019 Pages: 809 - 815
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation Ou YamaguchiKyoichi KairaHiroshi Kagamu Original Article 13 February 2019 Pages: 817 - 825
Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay Lydia SanchezAstrid BaclePascal Le Corre Original Article 13 February 2019 Pages: 827 - 835
Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects Chandra PrakashBin FanHua Yang Original Article 13 February 2019 Pages: 837 - 848
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer Toshio KawataMitsuo HigashimoriYusuke Tanigawara Original Article Open access 14 February 2019 Pages: 849 - 858
SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS Ian Joseph CohenHelen ToledanoShifra Ash Original Article 15 February 2019 Pages: 859 - 866
A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial Kazuhiro NishikawaKenta MurotaniToshimasa Tsujinaka Original Article 26 February 2019 Pages: 867 - 874
Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia Shaik Mohammad NaushadPatchava DorababuVijay Kumar Kutala Original Article 26 February 2019 Pages: 875 - 880
Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report Emmanuelle CoutyAlexis VallardNicolas Magné Original Article 26 February 2019 Pages: 881 - 892
Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model Daniel ThorpeMasooma SultaniAndrea Stringer Original Article 27 February 2019 Pages: 893 - 904
Determination of melphalan in human plasma by UPLC–UV method Liusheng HuangVincent CheahJanel Long-Boyle Original Article 13 February 2019 Pages: 905 - 910
Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer Wei ZhangLong ShiJianhui Cai Original Article 08 March 2019 Pages: 911 - 920
The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis Liangfeng ChenXiaobing HanLiangxin Chen Original Article 11 March 2019 Pages: 921 - 931
The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men Masaki ShiotaNaohiro FujimotoMasatoshi Eto Original Article 13 March 2019 Pages: 933 - 938
CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy Duo LiuXiang LiMei Dong Original Article 15 March 2019 Pages: 939 - 949
A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup Carlo LanciaJakob K. AnningaMarta Fiocco Original Article Open access 16 March 2019 Pages: 951 - 962
Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours Peng YuanJianzhong ShentuBinghe Xu Original Article 18 March 2019 Pages: 963 - 974
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer Davide MelisiRocio Garcia-CarboneroJosep Tabernero Original Article 18 March 2019 Pages: 975 - 991
Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38 Mariko IwaseKen-ichi FujitaYuji Kiuchi Short Communication 13 February 2019 Pages: 993 - 998
Eligibility criteria for phase I clinical trials: tight vs loose? Laeeq MalikDavid Lu Short Communication 27 February 2019 Pages: 999 - 1002
The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma Nicolas AlbinAdrien MonardJérémy Lapiere Letter to the Editor 04 March 2019 Pages: 1003 - 1005